Trial Profile
A phase 1 dose-escalation pharmacokinetic and pharmacodynamic study of TG01 tablets in combination with erlotinib in non-small cell lung cancer patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Apricoxib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Adastra Pharmaceuticals; Tragara Pharmaceuticals
- 18 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Mar 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov